Viewing nowHartbanjeong 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
LightPharmTech Co., Ltd.

MFDS item code 202001398 · Approved 2020.02.27 · Insurance code 690302370
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medicine is used for the treatment of essential hypertension and is also effective for heart failure patients who are not tolerant to ACE inhibitors (particularly NYHA class II to IV). Furthermore, it helps reduce the risk of mortality in patients with impaired left ventricular function after myocardial infarction. It is used in managing various cardiovascular diseases, thereby improving the patient's health.
1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, and the dose should be increased over several weeks, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years: Safety and efficacy have not been established.
This medication may cause serious harm to the fetus during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirming pregnancy. People who are allergic to this medication or its components, pregnant or potentially pregnant women, and breastfeeding women should not take this medication. Patients with severely impaired liver function, bile flow problems, severe renal impairment, and specific hereditary angioedema should also refrain from using this medication. Elderly patients, those with high potassium levels, mildly impaired liver function, and those with heart valve disorders or cardiovascular diseases should use this medication with caution. This medication may cause a sudden drop in blood pressure upon initial administration, potentially leading to dizziness or fainting; therefore, especially for patients undergoing dialysis or taking diuretics, it is crucial to start with a low dose and gradually increase. During medication use, blood pressure, renal function, and electrolyte levels should be monitored regularly for any abnormalities. Caution is needed when using this medication with potassium-sparing diuretics, potassium supplements, or drugs that can elevate potassium levels, as it may dangerously increase serum potassium levels. Additionally, concomitant use with non-steroidal anti-inflammatory drugs (NSAIDs) may diminish the blood pressure-lowering effect and adversely impact kidney function; therefore, careful monitoring is necessary in such cases. This medication is not recommended for breastfeeding women. If it must be used, breastfeeding should be discontinued. Overdose may lead to severe hypotension, decreased consciousness, or heart rhythm abnormalities, requiring immediate medical treatment. This medication is not recommended for children and adolescents, as safety and efficacy have not been established for this age group. Symptoms such as dizziness may occur while driving or operating machinery; caution is advised. Lastly, this medication should be kept out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a sealed container. Additionally, it should be kept in a cool place, below 30 degrees Celsius, to maintain its efficacy.
Oval-shaped, film-coated tablet with an orange color that shows a gray tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
LightPharmTech Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.